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The Pathogenesis and Prevention of Aortocoronary Vein Bypass Graft
Occlusion and Restenosis After Arterial Angioplasty: Role of Vascular
Injury and Platelet Thrombus Deposition
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Vascular injury during aortocoronary vein bypass graft
surgery and arterial angioplasty initiates platelet throm-
bus deposition and mandates antithrombotic therapy,
starting before the procedures to maximize protection
against occlusion. This has been shown in studies in
animals and in patients undergoing aortocoronary vein
bypass graft operation where dipyridamole therapy was
started before the operation, heparin was given intra-
operatively and combined dipyridamole and aspirin
therapy was started 7 hours after operation and mark-
edly reduced vein graft occlusion in patients with grafts
at both high and low risk for occlusion without increasing
bleeding. Other alternative regimens, particularly pre-
operative dipyridamole followed postoperatively with as-
pirin alone, offer a promising future. Therapy should
be continued for at least 1 year and perhaps indefinitely.
Coronary Artery Bypass Surgery
Mechanisms of occlusion. The mechanisms of acute
and chronic occlusion of aortocoronary vein grafts (Fig. 1)
parallel the pathogenesis of atherosclerosis, but differ from
it in the greater rate of progression during the early months
and years after operation (1). Vascular injury starts with
endothelial injury to the vein when it is harvested from the
leg and is probably increased by surgical handling, delays
before insertion in the aortocoronary position and the in-
creased shear forces of the arterial system (1,2). Beginning
with the first blood flow through the vein graft, there is
immediate platelet deposition, formation of mural thrombus
(evident histologically in 75% of vein grafts from patients
within 24 hours of operation) and entry of platelet factors
into the vessel wall (1-4). The internal mammary artery is
more protected from these problems, probably because of
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Control of coronary risk factors appears important for
long-term therapy to try to retard the atherosclerotic
and occlusive process that leads to approximately SO%
vein graft attrition by 10 years after operation. The pos-
sible role of cod liver oil and internal mammary artery
bypass is discussed.
Arterial angioplasty appears to cause deep arterial
injury that activates both platelets and the coagulation
system. These potentiate each other to form macroscopic
mural thrombus within 1 hour in more than 90% of
arteries that manifested deep arterial injury in pigs. Acute
platelet thrombus deposition was retarded but not elim-
inated by only certain platelet-inhibitor agents. Impli-
cations for ongoing trials, current empiric therapy and
future therapy are discussed.
(1 Am Coli CardioI1986;8:57B-66B)
more intact vasa vasorum, less extensive surgical handling
and previous adaptation to shear forces of the arterial sys-
tem.
Thrombosis. Because of the intraoperative initiation of
platelet thrombus deposition, it is probably optimal to apply
preventive therapy against thrombosis before operation, es-
pecially to protect high risk vein grafts in which blood flow
is low and the distal coronary artery is small « 1.5 mm)
(1,5). Angioscopy of vein grafts (6) has shown that tech-
nically faulty suturing at the distal anastomotic site, evident
only with this intraluminal examination, may be a cause of
lower flow or increased potential for occlusion. Thrombosis
is the main cause of occlusion within the first month after
operation (2,7).
Muscle cell proliferation. Smooth muscle cell prolifer-
ation is evident by histologic examination within I month
of operation and, with or without superimposed thrombosis,
is the main cause of late occlusion of vein grafts (7-9).
Smooth muscle cell proliferation results from stimulation
by the platelet-derived growth factor (or factors), which is
both mitogenic for growth and chemotactic for the migration
of smooth muscle cells from the media to the intima (1).
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Figure 1. Proposed pathogenesis of vein graft occlusion and chronic
occlusive disease. Thrombus can also contribute to late vein graft
occlusion. Lipoprotein entry and deposition are not evident until
after first postoperative year. Coronary risk factors and rheologic
forces probably perpetuate mild but chronic and repetitive endo-
thelial damage. This promotes the chronic disease in the wall of
the vein graft that is histologically indistinguishable from athero-
sclerosis in arteries (1,9). Mechanisms outlined with a rectangle
have been reduced or suppressed by therapy with dipyridamole
and aspirin in animal studies (see text). OJ = primary proliferation;rn = secondary proliferation.
Anticoagulant therapy. Although anticoagulant therapy
has no significant antiplatelet effects by itself, it seems to
be useful adjunctive therapy for situations with a high risk
of occlusion because the coagulation system, especially by
means of thrombin, activates platelets; in addition, thrombin
and platelets activate the coagulation system and the final
formation of fibrin stabilizes the platelet aggregates (14).
Thus, the use of the anticoagulant heparin during operation
(cardiopulmonary bypass) and, ideally, early after operation
is logical and useful. The use of dipyridamole before op-
eration was chosen because it decreased platelet activation,
maintained the platelet count during cardiopulmonary by-
pass and did not increase bleeding during operation (as
expected, because it does not increase the bleeding time in
doses used in humans); thus, it seemed potentially effective
and safe (15,16).
Aspirin plus dipyridamole. Because aspirin administered
before operation greatly increased bleeding in dogs (2,3,8)
and, in two of three studies, in humans (17-19), its use is
avoided, if possible, for 5 to 7 days before operation. Ex-
perimental studies in dogs (2,3,5,8) showed that adminis-
tration of dipyridamole 2 days before and including the
morning of operation and of aspirin within 7 hours after
operation significantly suppressed in vivo the mechanisms
that lead to the occlusion of vein grafts (deposition of plate-
lets on vein grafts, formation of mural thrombus and intimal
proliferation of smooth muscle cells).
Long-term adminstration of dipyridamole and aspirin may
be rational because these drugs reduce lipid incorporation
into vein grafts in nonhuman primates (20) and can reduce
platelet thrombus deposition in an experimental model of
deep arterial injury (21) and, thus, might reduce the for-
mation of new thrombus in patients, such as that found in
50 to 75% of vein grafts at autopsy (4,9). However, aspirin
alone and, particularly, low dose aspirin (I mg/kg per day)
also effectively reduced platelet thrombus deposition after
experimental arterial injury (21) and thus needs testing in
future trials.
Platelet inhibitor drug dosages. Platelet survival is
shortened in coronary artery disease and other arterial throm-
boembolic diseases. Thus, the ability in vivo to improve a
shortened platelet survival half-life or reduce indium-
Ill-labeled platelet deposition is good evidence for the
potential effectiveness of platelet inhibitor therapy (14). In
vitro tests of platelet function do not take into account plate-
let-arterial wall interaction. Therapeutic benefit with de-
creased thromboembolism in animals and humans has cor-
related with the improvement of a shortened platelet survival
(22-24). Drug dosages that improve a shortened platelet
survival half-life or decrease the deposition of indium-
Ill-labeled platelets in patients include administration of
both dipyridamole, 75 mg, plus aspirin, 325 mg, three times
daily, administration of dipyridamole, 100 mg, four times
daily when used alone (only when prosthetic material is the
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This proliferation (Fig. 1) can be: 1) a primary slow process
stimulated by only a single layer of platelet deposition, or
2) a "secondary proliferation" of smooth muscle cells into
organizing mural thrombus, which is a more rapid process
that may differ only quantitatively from primary prolifera-
tion (because of more massive platelet deposition) and prob-
ably is the predominant mechanism in vein grafts (I). A
mild decrease in the luminal diameter of the vein graft (an
average of 25% during the first year after operation) (10,11)
probably results from the first process. Smooth muscle cells
and fibroblasts synthesize connective tissue such as glycos-
aminoglycans and abnormal elastic tissue that can bind ex-
tracellular lipid and add to the bulk of the lesion (I). In
addition, smooth muscle cells and macrophages can engulf
lipid intracellularly by pinocytosis and contribute to addi-
tional lipid incorporation into the wall of the vein graft (1).
Lipid incorporation is not evident until after the first post-
operative year (9). These evolving histologic changes in the
vein graft are indistinguishable from arterial atherosclerotic
lesions (9) and progress more slowly beyond the first year
after operation (1,9,12,13).
Effect of drugs on mechanisms of occlusion. In gen-
eral, antithrombotic therapy that is started early, especially
before operation, has the best potential for reducing aor-
tocoronary vein graft occlusion. The ability of drugs to
suppress the factors leading to occlusion aids in the selection
of effective therapy, including how soon to start it and the
dosage. Because platelet-arterial wall interaction initiates
the occlusion of arteries and vein grafts (3,8,14), the choice
of antiplatelet therapy is logical.
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Table 1. The Mayo Clinic Study, Platelet-Inhibitor Therapy for
Patients Undergoing Aortocoronary Bypass Graft Operation*
Two days before operatIOn
Dipyridamole (Persantme). 100 mg. orally
four times dally
On day of operation
2 hours before operatIOn: dipyridamole,
100 mg. orally
I hour after operatIon: dipyridamole.
100 mg. via nasogastnc tube
(clamp. I V2 hours)
7 hours after operation: dipyridamole.
75 mg, and aspirin. 325 mg via
nasogastnc tube (clamp. 1'1> hours)
On day after operation and dally thereafter
Dipyridamole. 75 mg, and aspirin, 325 mg.
orally three tImes dally
*No other aspirin or prostaglandin-mhiblting drugs. especially non-
sterOIdal antIinflammatory agents (sulindac [Clinonlj would least inter-
fere), inhibitors of gastric aCid secretions (for example, cimetIdme or
ranitidine) or simultaneous antacid should be given. For patients with only
internal mammary artery bypass grafts and no vem grafts. empiric therapy
is adVised for 3 months to allow healIng at anastomotIc sites.
thrombogenic surface) or sulfinpyrazone, 200 mg, four times
daily (25-32). Aspirin alone is now being properly tested
and at low doses (0.5 to 1.0 mg/kg per day) seems promising
for future clinical use (21.30). Indeed, it will probably re-
place the combined use of dipyridamole and high doses of
aspirin as long-term therapy; results of ongoing trials are
awaited,
Clinical Trials
The Mayo Clinic study. We designed and conducted
the largest randomized, double-blind, placebo-controlled
clinical trial (this is the only level I trial-defined as a
randomized trial with a high statistical power [34,35]-for
aortocoronary vein bypass graft occlusion) using the ra-
tionale just outlined, starting therapy with dipyridamole 2
days before operation and aspirin 7 hours after operation
(Table 1). Angiography of vein grafts was performed early
(median 8 days; range 7 days to 6 months) after operation
in 360 patients (88%) and late (median I year) after oper-
ation in 343 patients (84%) (36,37). Early after operation,
the treated group had a marked reduction in the occlusion
of vein grafts per patient (p < 10 - 6, Fig. 2), per distal
anastomosis and per graft compared with the placebo group
(36). This large reduction in the rates of occlusion in treated
patients was present in more than 50 subgroups, including
patients at high or low risk for occlusion as determined by
blood flow in the vein graft, the diameter of the distal coro-
nary artery lumen measured during arteriotomy or presence
or absence of endarterectomy (36).
This preoperative initiation oftherapy was safe, Bleeding
as determined from measured hourly blood loss from chest
tubes, transfusion requirements for blood or blood com-
ponents or reoperation for bleeding did not differ between
the treated and placebo groups. One event of gastrointestinal
bleeding requiring blood transfusion occurred in a patient
in the placebo group (36).
New angiographic occlusion beyond the first month and
up to 1 year after operation in patients with grafts of all
types shown to be patent by angiography at the early study
(116 and 94 patients in the treated and the placebo group,
respectively) occurred in 16% of the treated and 27% of the
placebo group (Fig. 3) (37), This finding suggests that ther-
apy should be continued for at least 1 year after operation,
Platelet inhibitor therapy does not prevent the deposition
of a monolayer of platelets (3,21), which can stimulate a
Figure 2. Left, Occlusion rate of vein Distal Anastomoses Patients
graft-coronary artery distal anastomoses ct. 30 30 ........ ' 30totally occluded on angiography at t days
(/) Placebo ....
after operation, Right, Occlusion rate of .Q) ..
patients with one or more distal anasto- - .nl ..
moses occluded on angiography at t days ... ...
c 20 20 .. ,after operation (for group difference, p 0 ## 21
value and 95% confidence limits were as #(/) Placebo 18follows: at t = 10, p = 0,003,5 to 22%; ;:)
0 .......at t = 30, p = 0,0004, 7 to 23%; at 0 ........... 15
t = 120, P < 10- 6 , 14 to 30%), The 0 ~~ Treated, ....,,-
range of twas 7 to 180 days, The occlu- Q) 10 .~ 10 10~osion rates did not change from 120 to 180 > 9- Treated 8 8days after operation, when only six more nl
patients underwent angiography, N = to- :::J .",,- 4
tal number of distal anastomoses or pa- E 3 3:::J 0tients in treated and placebo groups at 10, U 20 40 60 80 100 120 20 40 60 80 100 120
30 and 120 days after operation, (Re- N (placebo) 341 362 513 123 130 182
printed with permission from Chesebro N (treated) 346 351 475 128 130 172
JH, et al. [36],)
t = interval from surgery to angiography in days
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Figure 3. Occlusion rates for all types of vein grafts. The rates
are expressed per distal anastomosis and per patient (proportion
with at least one occlusion). Occlusion is shown as events occur-
ring within I month (95% confidence limits for the per patient
difference. 8 to 24%), as new events occurring beyond 1 month
(in distal anastomoses and patients without occlusion within 1
month of operation) from angiography performed I year later (per
patient, p = 0.048; 95% confidence limits for the difference, 0
to 22%) and as events at a median of I year after operation (95%
confidence limits for the per patient difference, II to 34%). These
subsets include only patients who had angiography within I month
of operation and again I year later. Below each percentage is
shown the ratio of distal anastomoses or patients with occlusion
to total distal anastomoses or patients. (Reprinted with permission
from Chesebro JH, et al. [37].)
35 *Occlusion Iper 30 II
distal II 9anastomosis. 25
tIl I J
% 20 li ~ i ~~15
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......ASA-DIP-6- -2 -1 0 2 3 4
-.- ASA -iJr-... Sulf 6 Day therapy started
Figure 4. Relationship of vein graft occlusion to the day of starting
platelet inhibitor therapy (Rx) before (day - 2 or -1) or after
(day 1,2,3 or 4) operation. Studies in which therapy was studied
before or soon after operation were the most successful in pre-
venting occlusion. The time of angiography (Angio) and the drugs
administered are shown by the symbols and lines in the key for
placebo (open symbol) and treated (closed symbol) groups. From
left to right, at day - 2, the three trial results are at 10 days, 4
months and 12 months after operation (36,37); at day - I (all
patIents also received warfarin therapy for 3 months), at 6 months
after operation (39); at day I, at 7 to 14 days after operation (40),
at 4Y2 months after operation (41) and at 4 months after operation
(42); at day 2, two subgroups at 12 months after operation (43);
at day 2'/2 (all patients also received warfarin therapy for 3 months),
at 12 months after operation (44); at day 3, two subgroups at 12
months after operation (43); at day 3'12, at 24 months after op-
eration (45) and at 6 months after operation (46); and at day 4,
two subgroups at 12 months after operation (47). ASA = ace-
tylsalicylic acid (aspirin); DIP = dipyridamole; Sulf = sulfin-
pyrazone.
otherwise resulted). Discontinuation of platelet-inhibitor
therapy because of symptoms (headache or gastrointestinal
upset) was necessary in 6% of 202 treated patients and 2%
of 205 patients receiving placebo (36,37).
Comparison with other studies. The importance of
perioperative platelet-inhibitor therapy started within at least
48 hours of operation for reducing overall occlusion of vein
grafts was shown in our level I study (36,37) and five level
II studies (39-43)-defined as randomized trials with a
low statistical power (34)-(Fig. 4). Starting therapy more
than 48 hours after operation did not reduce occlusion of
vein grafts (five level II studies [43-47]) (Fig. 4). Only
preoperative therapy reduced occlusion in vein grafts at high
risk for occlusion in a comparison of results of studies
(36,38,43) that analyzed risk factors for occlusion (such as
low blood flow in the vein graft or small luminal diameter
of the distal coronary artery) (Table 2). A high proportion
of grafts were at higher risk-two-thirds had a blood flow
of 80 mllmin or less, and more than half were anastomosed
to coronary arteries with a luminal diameter of 1.5 mm or
less (Table 2). In addition, analysis of risk factors for oc-
CORONARY BYPASS SURGERY
Day of Antiplatelet Rx and Occlusion
27%
25/94
Per patient
2%
7/329
Per distal anastomosis
ALL TYPES OF GRAFTS
Occlusion Rates ~ 1 Month After Operation
22% 26/120
Occlusion Rates Late After Operation
42%
o Treated 51/120
~Placebo
30
20
10
o '---===----
50
40
30
20
10
o '--_'"'-..1-__
30 New Occlusion Rates After 1 Month
20
10
o '---'---'---
Occlusion
rates
(%)
slow and gradual increase in smooth muscle cell prolifer-
ation. Thus, not unexpectedly, small decreases in the lu-
minal diameter of patent vein grafts (as measured by quan-
titative angiography) during the first year after operation
were not prevented by therapy with dipyridamole and aspirin
(an average decrease of 1.19 mm or 24% in the luminal
diameter in the placebo group and 1.15 mm or 23% in the
treated group) (10).
This platelet inhibitor therapy was both safe and well
tolerated. No patient developed angina from the vasodilator
effects of dipyridamole, even when given as 100 mg four
times daily for 2 days before operation and 100 mg orally
2 hours before operation to patients with unstable angina
(care was taken to avoid giving doses less than 4 hours
apart). Rapid absorption of dipyridamole in a small patient
(especially if administered less than 4 hours between doses)
with unstable angina could theoretically induce angina be-
cause dipyridamole inhibits the cellular uptake of adenosine,
which causes vasodilation; the vasodilator effect can be
reversed immediately with 100 to 125 mg of theophylline
(which increases the cellular uptake of adenosine) admin-
istered intravenously (38). Patients were instructed to take
their platelet inhibitor therapy three times daily at times that
best fit their daily schedule (including with meals if it was
most convenient or if headache or gastrointestinal upset
JACC Vol. 8, No 6
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Table 2. Occlusion Late After Operation in All Individual Vein
Grafts According to Blood Flow and Luminal Diameter of the
Coronary Artery
*Data are missing for nme patients In the treated and seven m the
placebo group.
tData are mIssing for six patients in the treated and two m the placebo
group. (Reprinted with permIssion from Chesebro lH, et al [37J.)
clusion is important to ensure equality of treatment groups
in a study and to compare studies from different centers.
The only other study (39) starting platelet-inhibitor therapy
before operation did not determine risk factors for occlusion.
Different types of vein grafts such as the noncircular
sequential graft (usually two distal anastomoses to branches
of the same coronary artery) do not respond as well to
therapy with dipyridamole and aspirin, perhaps because of
risky technical problems of a short radius of curvature, with
a potential for turbulent flow or kinking and competitive
flow (37). Thus, rates of occlusion should also be listed by
type of graft. One or two internal mammary artery grafts
should be anastomosed to the one or two most major coro-
nary arteries (especially the left anterior descending coro-
nary artery) because of the very low rates of occlusion both
early and 10 years after operation and the improved survival
10 years after operation (48,49).
In a previous trial (50) of oral anticoagulation in aor-
tocoronary vein bypass graft operation, heparin therapy was
started 6 hours after operation and given together with di-
pyridamole in all patients for 7 days before, and patients
were randomly assigned to receive oral anticoagulant ther-
apy or no further therapy. Angiography of vein grafts was
performed 8 weeks after operation. The control group of
that trial (50) and the placebo group in our trial (36) had
similar rates of occlusion at the same time after operation,
but our patients treated perioperatively with dipyridamole
and aspirin had a 60% lower rate of occlusion than did the
group treated with oral anticoagulation alone (Table 3).
Nevertheless, on the basis of this level I study on antico-
agulants, in patients intolerant to platelet inhibitors, heparin
started early after operation and followed up by oral anti-
coagulants appears to be the regimen of choice.
Anticoagulant therapy alone has four disadvantages for
preventing occlusion of vein grafts: 1) it does not decrease
Treated Group Placebo Group
(no. grafts occluded/total no.) (%)
Group (Reference) DIstal Anastomosis Patient*
Placebo (36) IS (513) 30 (172)t
DIP + ASA (36) 4 (475) 10 (l82)t
Control (50) 15 (238) 33 (85)§
ACRx (50) 10 (251) 19 (89)§
the platelet deposition that initiates occlusion of vein grafts,
2) it cannot be started until after operation, 3) it necessitates
laboratory monitoring, and 4) it is probably not as effective
as preoperative therapy with dipyridamole and early post-
operative therapy with aspirin (Table 3). However, com-
bined therapy with an anticoagulant and a platelet inhibitor
is probably more effective than either one alone because the
coagulation system (especially by means of thrombin) ac-
tivates platelets and platelet activation stimulates the clotting
system (1,14,51).
Therapy with lower dose aspirin at 100 mg/day started
the day after operation was investigated in one small level
II trial (42) in 46 patients (22 treated and 24 placebo) who
underwent angiography 4 months after operation. Unfor-
tunately, there was an imbalance in the baseline character-
istics and a very high occlusion rate in the placebo group
(35% of distal anastomoses and 62% of patients with one
or more occlusions) compared with our placebo group at 4
months (15% of distal anastomoses and 30% of patients
with one or more occlusions) (Fig. 2). Although the occlu-
sion rates were significantly (p < 0.02) reduced in the treated
group to 19% of distal anastomoses and 35% of patients
(42), the results did not approach our markedly better out-
come after perioperative treatment with dipyridamole and
aspirin, which reduced the occlusion rates to 4% of distal
anastomoses and 10% of patients (Fig. 2.).
A subsequent levelJ/ study by the same group (19) com-
paring aspirin, 100 mg/day, (starting a day before operation)
with oral anticoagulation (started after operation) showed
excessive bleeding in the aspirin group, relatively high oc-
clusion rates in both treated groups and no difference in
occlusion rates between the aspirin and anticoagulation groups
in the approximately 70% of patients who had repeat an-
giography. Thus, preoperative therapy with dipyridamole
and early postoperative combined therapy with aspirin are
*Proportion of patients WIth one or more occlUSIOns. tp < 0.000001;
95% confidence interval of the difference 14 to 30%. §p < 0.02.
ACRx = anticoagulant therapy; DIP + ASA = dIpyridamole and aspirin.
(ModIfied with permission of S. Karger AG from Chesebro JH, Fuster V.
Platelet-mhibitor drugs before and after coronary artery bypass surgery and
coronary angioplasty: the basis of their use, data from animal studies,
clinIcal trial data, and current recommendations. Cardiology, 1986 [in
press].)
% Occlusion (total no. at risk) per:
Table 3. Comparison of Anticoagulant Therapy With
Preoperatively and Postoperatively Administered Dipyridamole
and Aspirin
9/15 (60)
391122 (32)
251117 (21)
73/254 (29)
28/61 (46)
35/120 (29)
10/68 (15)
73/249 (29)
3/10 (30)
8/128 (6)
121126 (10)
23/264 (9)
9/45 (20)
101124 (8)
5/92 (5)
24/261 (9)
Blood flow (ml/min)
:0:40
41 to 80
280
Total*
Luminal diameter (mm)
:0: 1.0
1.1 to 1.5
>1.5
Totalt
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extremely effective and safe management practices against
which future therapies should be compared.
Aspirin alone, especially low dose at 1 mg/kg per day,
has excellent potential, as suggested by the previously men-
tioned level II study (42) and studies (21) of platelet throm-
bus deposition after deep arterial injury in pigs. In this in
vivo model, aspirin (I mg/kg per day) was as effective as
dipyridamole and aspirin (20 mg/kg per day). Aspirin alone
was effective in two level I studies (52,53) of patients with
unstable angina in which the incidence of death and nonfatal
myocardial infarction was reduced. Another level II study
(43) showed favorable results for aspirin in coronary bypass
graft operations, but it did not benefit high risk patients
because of postoperative initiation of therapy. Other studies
with aspirin alone are pending. Even low dose aspirin before
operation leads to increased perioperative bleeding (19).Thus,
preoperative therapy with dipyridamole and intraoperative
therapy with heparin will remain important for safe and early
protection against acute platelet thrombus deposition, but
aspirin alone, especially at low doses (0.5 to 1.0 mg/kg per
day) will probably succeed combined dipyridamole and as-
pirin therapy in the future for long-term postoperative use.
Platelet inhibitor beyond the first year. The value of
continued platelet-inhibitor therapy beyond the first year
after operation has not been evaluated by a clinical trial.
However, continued and indefinite use of platelet-inhibitor
therapy is rational to try to reduce new mural thrombus
formation because I) mural thrombus can organize and lead
to growth of lesions that may be rapid (Fig. I) (1) and may
contribute to the continued attrition of vein grafts more than
10 to 12 years after operation (1,12); 2) mural thrombus
may grow and precipitate acute occlusion and acute myo-
cardial infarction, which often can be interrupted by throm-
bolytic therapy; and 3) mural thrombus is probably an ever
present problem because it was found in 50 to 75% of vein
grafts at autopsy in patients who died 1 year to more than
4 years after operation (4,9). Furthermore, platelet-inhibitor
therapy can suppress lipid incorporation into the wall of the
vein graft in monkeys (20) and, thus, may suppress another
mechanism that seems to be involved in the long-term at-
trition of vein grafts (Fig. 1) (13). The histologic changes
in vein grafts are indistinguishable from those of coronary
artery disease and progress at a slower rate after the first
postoperative year (1,9). Thus, the results of our ongoing,
double-blind, randomized trial of dipyridamole and aspirin
versus placebo for the suppression of the angiographic pro-
gression of coronary artery disease over 5 years (40 to 50%
of patients are estimated to have progression over this time)
in patients who have not had a coronary bypass graft op-
eration (54) may be helpful in determining whether platelet-
inhibitor therapy should be continued indefinitely.
Control of risk factors. It also seems important to con-
trol coronary risk factors because most of them are asso-
ciated with propagation of endothelial injury, shortening of
platelet survival and, thus, probably enhancement of the
platelet-arterial wall interaction (Fig. 1) (1,13,14). Cessa-
tion of tobacco use, lowering the levels of total serum cho-
lesterol (as low as possible and preferably to less than 200
mg/dl) and triglycerides, elevation of high density lipopro-
tein cholesterol, control of even borderline hypertension and
optimal control of diabetes mellitus are worthy goals. Weight
control and regular sustained exercise can also assist in
reducing these risk factors.
The potential role of therapy with cod liver oil, a source
of eicosapentaenoic acid, needs to be determined. This acid
competes with arachidonic acid for cyclooxygenase, which
results in a decreased production of thromboxane Az. More
importantly, metabolism of eicosapentaenoic acid may
produce only a weakly aggregatory prostenoid, thrombox-
ane A3 , by platelets and an antiaggregatory, prostenoid,
prostacyclin 13 , by the vessel wall (55-57). Administration
of cod liver oil results in a decreased platelet count, de-
creased platelet aggregation, decreased total serum choles-
terol, decreased intimal hyperplasia in vein grafts and in-
creased high density lipoprotein cholesterol and bleeding
time (55,58). Thus, the combined effects on platelets, the
arterial wall and serum lipids suggest that cod liver oil may
be ideal short- and long-term therapy in patients with coro-
nary artery disease who have had a coronary bypass graft
operation. Further studies are necessary.
Coronary Angioplasty
Percutaneous transluminal coronary angioplasty is an im-
portant alternative for revascularization in patients with in-
capacitating single vessel (59,60) or multivessel (61,62)
coronary artery disease. Fracture or splitting of the stenotic
lesion and stretching or expansion of the external diameter
of the artery are probable mechanisms of a successful an-
gioplasty that greatly reduce the luminal obstruction caused
by an atherosclerotic lesion (63-65). Denudation of endo-
thelium, deposition of platelets and formation of mural
thrombus are acute changes found in dogs and pigs after
arterial angioplasty (66,67). Deposition of platelets and
thrombus is probably an important cause of acute occlusion
(64,67,68) and restenosis (67-69). Restenosis is the" Achil-
les heel" of angioplasty and occurs in 25 to 35% of pa-
tients within 6 months of the procedure (70,71). Thus, it
is important to elucidate the pathophysiologic response to
arterial injury and the natural history of the acute deposi-
tion of platelets and thrombus, as was recently reported (67),
to try to determine mechanisms of restenosis.
Proposed pathogenesis of restenosis. Arterial angio-
plasty of even a normal artery often causes more than mere
endothelial denudation; more importantly, it may cause se-
vere or deep arterial injury with a tear into the media. In
patients, similar severe injury that splits, fractures or tears
the atherosclerotic plaque appears necessary for a successful
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angioplasty (63-65). This deep injury exposes the flowing
blood to collagen fibrils, elastic tissue, smooth muscle cells
and, in many patients, the fatty gruel of the atherosclerotic
plaque, all of which activate platelets and the intrinsic co-
agulation system; released tissue thromboplastin activates
the extrinsic clotting system (1,14,51). In addition, platelet
activation facilitates the activation of the clotting system.
Thus, it is not surprising that as evaluated in the pig model,
this deep arterial injury leads to very high quantitative plate-
let deposition (measured with indium-Ill-labeled plate-
lets), with formation of mural thrombus in more than 90%
of arteries within I hour of the angioplasty procedure in
spite of full heparinization (100 U/kg bolus intravenously
just before the procedure, activated partial thromboplastin
time increased to four to five times control I hour after the
bolus and only dose of heparin) (67,72).
Superficial injury with only endothelial denudation and
no injury below the internal elastic lamina causes only mild
platelet deposition, usually with only a single layer of plate-
lets and no formation of macroscopic mural thrombus (67,72).
Deposition of platelets remained high 24 hours after the
angioplasty procedure in our pig model, but was markedly
reduced 4 days after the procedure when there was partial
regrowth of endothelial-like cells (determined by scanning
electron microscopy) and was unchanged from baseline at
7 days after the procedure when the regrowth of endothelial-
like cells was largely complete (67). Thus, the endothelium
and regrowth of endothelial-like cells seem to protect against
platelet deposition. Intimal smooth muscle cell proliferation
was mild and patchy 7 days after the procedure, and sig-
nificantly greater and more uniform 2 weeks to 2 months
after the procedure (67). Complete thrombotic occlusion
occurred in 7% of 27 arteries within I hour (72) and in II %
of 38 pigs after variable periods of follow-up (one occlusion
each at I, 4, 14 and 30 days, respectively after the proce-
Figure 5. Pig artery at site of dilation 30 days after arterial balloon
angioplasty. Left, Macroscopic appearance of a significant stenotic
lesion. Right, Histologic section of same lesion shows that ob-
struction is due to organization of mural thrombus. (Lason's elas-
tic-van Gieson; original magnification, x 64.) (Reprinted by per-
mission of The American Heart Association, Inc. from Steele PM,
eta\. [67].)
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Figure 6. Proposed pathophysiologic mechanisms of restenosis
after arterial angioplasty. Pathway 1, the organization of mural
thrombus, is probably the major mechanism of restenosis. Pathway
2, smooth muscle cell proliferation, probably makes a smaller
contribution. Vasoconstriction (spasm) (pathway 3) is always pres-
ent adjacent to the dilated region after arterial angioplasty in the
pig carotid artery and is directly related to the severity of platelet
deposition (73, 74), but makes an uncertain contribution to reste-
nosis. Remodeling (pathway 4) is hypothetical, but it may be
closely related to pathway I (see text). Mechanisms outlined with
a rectangle have been reduced or suppressed by selective platelet-
inhibitor therapy in our pig model of angioplasty (68) (see text).
dure). In one animal, significant stenosis was present I
month after angioplasty and was shown by histologic ex-
amination to be due to organization of mural thrombus
(Fig. 5).
Vasoconstriction does not occur in the region of balloon
dilation because of the necrosis of smooth muscle cells in
the media (67). However, variable degrees of vasoconstric-
tion occur proximally and distally to the dilated region. The
degree of vasoconstriction correlates directly with the se-
verity of platelet deposition and can be significantly de-
creased by reducing platelet deposition with low dose aspirin
(lmg/kg per day) (73,74).
Our hypothesis for the development of restenosis after
arterial angioplasty is summarized in Figure 6. The pre-
dominant mechanism appears to be pathway 1, the orga-
nization of mural thrombus at sites of severe arterial injury,
particularly if angioplasty is unsuccessful and the underlying
stenosis and blood stasis persist. Smooth muscle cell pro-
liferation as a result of platelet deposition, probably also
contributes, but to a less significant degree. The role of
vasoconstriction in humans remains undefined. but any con-
tribution from this mechanism seems to be linked, in part,
to the severity of platelet deposition. Even asymptomatic
vasoconstriction or incomplete dilation of a stenotic lesion
could alter blood flow and increase shear forces ("drag
forces" parallel to the lumen), which leads to increased
platelet deposition (75,76). Remodeling at the site of injury
with an accumulation of connective tissue, probably syn-
thesized by fibroblasts and smooth muscle cells, is noted 2
weeks to 2 months after angioplasty. This consists of con-
nective tissue, lacking the normal histologic network of
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elastic fibers, within an apparent tear or gap in the media
of the artery; it is of uncertain importance for the occurrence
of stenosis, but its development can be initiated by acute
platelet thrombus deposition and later organization of throm-
bus and, thus, is probably interrelated with pathway I.
Drug intervention. Therapy for reducing the incidence
of restenosis remains to be established. Because of the pow-
erful stimulus for platelet thrombus deposition acutely, it is
likely that the combination of heparin and platelet-inhibitor
therapy will be required for at least 24 hours and perhaps
longer. We have measured thrombus and indium-Ill-labeled
platelet deposition 1 hour after angioplasty in pigs with and
without the administration of different platelet-inhibitor drugs
at different dosages, starting before the procedure to eval-
uate the potential effectiveness and future use in a clinical
trial. We would consider spending the time, effort and money
for a prospective, randomized, double-blind trial in patients
only if the therapy reduced platelet deposition 1 hour after
angioplasty in our pig model. When administered in addition
to heparin, only partially successful therapy thus far has
included dipyridamole (2.5 mg/kg per day) and aspirin (20
mg/kg per day), aspirin alone (l mg/kg per day) and an
experimental platelet-inhibitor drug, anagrelide (adminis-
tered with or without the addition of dipyridamole and as-
pirin) (21). Also in combination with heparin, therapy that
was ineffective included low molecular weight dextran,
prostacyclin (prostaglandin 12), prostaglandin E h aspirin alone
(20 mg/kg per day), dipyridamole alone, sulfinpyrazone,
ticlopidine (administered 4 days before the procedure), ve-
rapamil, nifedipine and the thromboxane Az receptor blocker
SQ 29,548 (21,73,76,77). Therefore, other approaches are
needed.
Platelets are activated via three pathways-adenosine
diphosphate, prostaglandins (especially thromboxane A2)
and platelet-activating factor, but platelet inhibitor drugs
probably only inhibit the prostaglandin pathway and, thus,
are incomplete inhibitors of platelet activation (14,51). Thus,
other strategies need investigation such as blockade of fi-
brinogen receptors on the platelet (which promote aggre-
gation), blockade of von Willebrand factor receptors on the
platelet and arterial wall (important in platelet adhesion) and
blockade of platelet-derived growth factor receptor (which
stimulate smooth muscle cell proliferation).
No level I studies of drug therapy for the prevention of
restenosis have been reported. One level II study (78) sug-
gests no benefit from the use of low molecular weight dex-
tran in patients. Another level II study (79), which included
patients who did not have occlusion within 48 hours of
angioplasty found restenosis in more than 25% of a group
of patients treated with warfarin and a group treated with
aspirin (325 mg/day) (79).
Current recommendations. It is not known whether
any platelet inhibitor therapy will be effective for reducing
the incidence of restenosis after angioplasty. We suggest
that all patients receive heparin (100 U/kg bolus) in the
catheterization laboratory just before starting the angioplasty
procedure, and that this be followed within 1 hour by an
intravenous infusion of heparin at approximately 15 U/kg
per hour for 18 to 24 hours after the procedure or until 7
A.M. the next day when heparin therapy can be stopped and
the arterial sheath removed to 2 to 4 hours later. If the
procedure is complicated by a large intimal flap or if throm-
bus was identified by angiography either before or after the
angioplasty procedure, we empirically continue the heparin
infusion for at least 48 hours (the arterial sheath can be
removed after discontinuing heparin after 48 hours or, if
necessary, after 24 hours [after decreasing the heparin in-
fusion to 7.5 U/kg per hour for 3 to 4 hours and compressing
the puncture site for 30 minutes by an experienced individual
and by a compressive dressing thereafter before resuming
the herapin infusion at 15 U/kg per hour]).
The empiric platelet inhibitor therapy that we are cur-
rently testing in a prospective, randomized, double-blind,
placebo-controlled clinical trial starting 1 day before the
angioplasty procedure is dipyridamole, 225 mg/day, and
aspirin, 975 mg/day, in three divided doses. A dose is ad-
ministered 1 to 2 hours before the angioplasty procedure
and then dipyridamole and aspirin in the dosage just de-
scribed is continued for 6 months. All of our patients in this
trial receive heparin for 18 to 24 hours and are restudied 6
months after angioplasty. This proposed therapy is con-
sistent with the effectiveness of this drug combination for
markedly reducing thrombotic occlusion in aortocoronary
vein bypass grafts (36,37). From our studies in pigs, an
equally rational approach to platelet-inhibitor therapy would
be to use aspirin, 80 mg/day, starting the day before the
procedure and administering a dose 1 to 2 hours before
angioplasty; however, this low dose of aspirin has no track
record thus far in trials of antithrombotic therapy in arterial
thromboembolic disease (except for a small level II study
[42] previously discussed). New and powerful strategies for
suppressing platelet thrombus deposition are needed, but
will probably only be used on a short-term basis because
of a high risk of bleeding.
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